Consolidated Statements of Stockholders Equity (Deficit) - USD ($)
$ in Thousands |
Total |
Common Stock |
Additional Paid-In Capital |
Accumulated Other Comprehensive Income (Loss) |
Accumulated Deficit |
| Beginning balance (in shares) at Dec. 31, 2017 |
|
28,406,026
|
|
|
|
| Beginning balance at Dec. 31, 2017 |
$ (79,588)
|
$ 28
|
$ 220,117
|
$ 115
|
$ (299,848)
|
| Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
| Net loss |
(21,558)
|
|
|
|
(21,558)
|
| Share-based compensation |
13,494
|
|
13,494
|
|
|
| Common stock sales (in shares) |
|
5,893,428
|
|
|
|
| Common stock sales |
13,568
|
$ 6
|
13,562
|
|
|
| Equity instrument exercises (in shares) |
|
4,753,858
|
|
|
|
| Equity instrument exercises |
60,892
|
$ 5
|
60,887
|
|
|
| Reclassification of liability-classified stock-based compensation |
(12)
|
|
(12)
|
|
|
| Other |
$ (113)
|
|
(30)
|
(83)
|
|
| Ending balance (in shares) at Dec. 31, 2018 |
39,053,312
|
39,053,312
|
|
|
|
| Ending balance at Dec. 31, 2018 |
$ (13,124)
|
$ 39
|
308,018
|
32
|
(321,213)
|
| Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
| Net loss |
(25,614)
|
|
|
|
|
| Share-based compensation |
425
|
|
425
|
|
|
| Common stock sales (in shares) |
|
11,999,597
|
|
|
|
| Common stock sales |
10,840
|
$ 12
|
10,828
|
|
|
| Equity instrument exercises (in shares) |
|
2,250
|
|
|
|
| Equity instrument exercises |
4
|
|
4
|
|
|
| Other |
$ (259)
|
|
0
|
(259)
|
|
| Ending balance (in shares) at Dec. 31, 2019 |
51,055,159
|
51,055,159
|
|
|
|
| Ending balance at Dec. 31, 2019 |
$ (27,728)
|
$ 51
|
$ 319,275
|
$ (227)
|
$ (346,827)
|